Davey MG, Miller N, McInerney NM (2021) A review of epidemiology and cancer biology of malignant melanoma. Cureus 13:e15087. https://doi.org/10.7759/cureus.15087

Article  PubMed  PubMed Central  Google Scholar 

https://www.wcrf.org/cancer-trends/skin-cancer-statistics/

Hill GJ 2nd, Krementz ET, Hill HZ (1984) Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53:1299–1305. https://doi.org/10.1002/1097-0142(19840315)53:6%3c1299::aid-cncr2820530613%3e3.0.co;2-4

Article  PubMed  Google Scholar 

Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917–924. https://doi.org/10.1200/JCO.2010.32.2537

Article  PubMed  PubMed Central  Google Scholar 

Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516. https://doi.org/10.1056/NEJMoa1103782

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780–2788. https://doi.org/10.1200/JCO.2014.58.3377

Article  CAS  PubMed  Google Scholar 

Tamemasa D (2014) Novel immunotherapy in oncology. In: Furue M (ed) Malignant tumors of the skin: latest advances in diagnosis and treatment for practical applications. Nakayama, Shoten (in Japanese)

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915. https://doi.org/10.1038/nm1100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Japan Clinical Oncology Society (2023) (ed) Guidelines for Cancer Immunotherapy, 3rd edition. Kanehara Shuppan, Tokyo (in Japanese)

Japan Clinical Oncology Society (2019) (ed) Guidelines for Cancer Immunotherapy, 2nd edn. Kanehara Shuppan, Tokyo (in Japanese)

Japan Clinical Oncology Society (2016) (ed) Guidelines for cancer immunotherapy, 1st edn. Kanehara Shuppan, Tokyo (in Japanese)

Young T, Hopewell S (2011) Methods for obtaining unpublished data. Cochrane Database Syst Rev 11:MR000027

Higgins JP, Altman DG, Gøtzsche PC, Cochrane Bias Methods Group, Cochrane Statistical Methods Group et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928

Fagerlin A (2011) “Chapter 7: quantitative information”. In: Fischhoff B, Brewer NT, Downs JS (eds) Communicating risks and benefits: an evidence-based User’s Guide, pp 57–61. Annapolis: Food and Drug Administration (FDA). http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM268069.pdf

Naylor CD, Chen E, Strauss B (1992) Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 117:916–921

Article  CAS  PubMed  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring incomsistency in meta-analysis. BMJ 327:557–560

Article  PubMed  PubMed Central  Google Scholar 

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

Article  CAS  PubMed  Google Scholar 

Light RJ, Pilemer DB (1984) Summing up: the science of reviewing research. Harvard University Press, Cambridge

Book  Google Scholar 

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

Article  CAS  PubMed  Google Scholar 

Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

Article  CAS  PubMed  PubMed Central  Google Scholar 

StataCorp (2022) Stata Statistical Software: Release 17. StataCorp LP, College Station

Google Scholar 

Newlands ES, Oon CJ, Roberts JT et al (1976) Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma. Br J Cancer 34:174–179. https://doi.org/10.1038/bjc.1976.140

Article  CAS  PubMed  PubMed Central  Google Scholar 

Livingston PO, Wong GY, Adluri S et al (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036–1044. https://doi.org/10.1200/JCO.1994.12.5.1036

Article  CAS  PubMed  Google Scholar 

Kirkwood JM, Ibrahim JG, Sosman JA et al (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370–2380. https://doi.org/10.1200/JCO.2001.19.9.2370

Article  CAS  PubMed  Google Scholar 

Bystryn JC, Zeleniuch-Jacquotte A, Oratz R et al (2001) Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 7:1882–1887

CAS  PubMed  Google Scholar 

Hersey P, Coates AS, McCarthy WH et al (2002) Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 20:4181–4190. https://doi.org/10.1200/JCO.2002.12.094

Article  CAS  PubMed  Google Scholar 

Schadendorf D, Ugurel S, Schuler-Thurner B et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563–570. https://doi.org/10.1093/annonc/mdj138

Article  CAS  PubMed  Google Scholar 

et al (2007) Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 25:2078-2085. https://doi.org/10.1200/JCO.2006.10.1709

Testori A, Richards J, Whitman E et al (2008) Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100–21 Study Group. J Clin Oncol 26:955–962. https://doi.org/10.1200/JCO.2007.11.9941

Article  CAS  PubMed  Google Scholar 

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. https://doi.org/10.1056/NEJMoa1003466

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 Peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119–2127. https://doi.org/10.1056/NEJMoa1012863

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eggermont AM, Suciu S, Rutkowski P et al (2013) Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol 31:3831–3837. https://doi.org/10.1200/JCO.2012.47.9303

Article  CAS  PubMed  Google Scholar 

Jha G, Miller JS, Curtsinger JM et al (2014) Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma. Am J Clin Oncol 37:261–265. https://doi.org/10.1097/COC.0b013e318277d5c8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lawson DH, Lee S, Zhao F et al (2015) Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol 33:4066–4076. https://doi.org/10.1200/JCO.2015.62.0500

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faries MB, Mozzillo N, Kashani-Sabet M et al (2017) Long-term survival after complet